首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Early Changes in T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV Infection.
【24h】

Early Changes in T-Cell Activation Predict Antiretroviral Success in Salvage Therapy of HIV Infection.

机译:T细胞活化的早期变化预测抗逆转录病毒疗法在HIV感染的挽救疗法中的成功。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE:: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy. DESIGN:: Observational cohort study. SETTING:: Institutional HIV clinic. SUBJECTS:: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION:: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES:: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models. RESULTS:: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not. CONCLUSIONS:: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.
机译:目的:由于有效的抗逆转录病毒疗法(ART)会降低免疫激活,因此我们推测免疫激活的早期变化与随后对该疗法的病毒学应答有关。设计::观察性队列研究。地点:机构艾滋病诊所。研究对象:34名成人HIV患者在目前的抗逆转录病毒治疗方案中发生病毒学衰竭。干预::改变患者医生选择的打捞方案。主要观察指标:入选后基线,第2、4、8和24周的免疫活化程度。通过比例风险(PH)模型分析数据。结果:PH模型显示,基线和第2周之间CD4 T细胞CD38(P = 0.02)或CD95(P = 0.02)表达的降低与病毒抑制的可能性增加有关。 Kaplan-Meier分析表明,在治疗的前2周内CD38 T细胞表达CD38(P = 0.003)或CD95(P = 0.08)降低的患者比未接受治疗的患者更有可能实现病毒抑制。结论:挽救疗法2周内CD38和CD95的CD4 T细胞表达降低与随后的病毒抑制有关。监测CD38和CD95可允许较早评估对ART的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号